AboutSynthorx

Company Summary

Synthorx is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin in a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development for the treatment of solid tumors as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries by Floyd Romesberg and The Scripps Research Institute. The company is headquartered in La Jolla, Calif.

The Synthorx team

Technology